Puma Biotechnology
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. The last earnings update was 14 days ago. More info.
Add to Portfolio Compare Print
- Puma Biotechnology has significant price volatility in the past 3 months.
PBYI Share Price and Events
7 Day Returns
1 Year Returns
PBYI Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Puma Biotechnology (PBYI) | -7.8% | -55.1% | -42.7% | -70.5% | -59% | -80% |
| US Biotechs | 1% | -0% | -3.2% | -4.6% | 3.8% | 9.7% |
| US Market | 0.2% | -1.6% | 2.4% | 2.9% | 36.1% | 41% |
1 Year Return vs Industry and Market
- PBYI underperformed the Biotechs industry which returned -4.6% over the past year.
- PBYI underperformed the Market in United States of America which returned 2.9% over the past year.
PBYI Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Puma Biotechnology
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Puma Biotechnology.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 8 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 11.5% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.38 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.383 (1 + (1- 21%) (30.42%)) |
1.48 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.48 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.48 * 5.96%) |
11.55% |
Discounted Cash Flow Calculation for NasdaqGS:PBYI using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Puma Biotechnology is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 11.55%) |
|
|---|---|---|---|
| 2019 | 2.50 | Analyst x2 | 2.24 |
| 2020 | -9.67 | Analyst x3 | -7.77 |
| 2021 | 66.00 | Analyst x2 | 47.55 |
| 2022 | 164.50 | Analyst x2 | 106.25 |
| 2023 | 234.00 | Analyst x2 | 135.49 |
| 2024 | 293.09 | Est @ 25.25% | 152.13 |
| 2025 | 347.30 | Est @ 18.5% | 161.61 |
| 2026 | 395.10 | Est @ 13.77% | 164.82 |
| 2027 | 436.41 | Est @ 10.45% | 163.20 |
| 2028 | 471.93 | Est @ 8.14% | 158.21 |
| Present value of next 10 years cash flows | $1,083.73 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $471.93 × (1 + 2.73%) ÷ (11.55% – 2.73%) |
$5,497.72 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $5,497.72 ÷ (1 + 11.55%)10 |
$1,843.10 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $1,083.73 + $1,843.10 |
$2,926.83 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $2,926.83 / 38.61 |
$75.8 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $75.80 |
| Current discount | Discount to share price of
$15.30
= -1 x ($15.30 - $75.80) / $75.80 |
79.8% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Puma Biotechnology's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Puma Biotechnology's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Puma Biotechnology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Puma Biotechnology's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $-2.60 |
| NasdaqGS:PBYI Share Price ** | NasdaqGS (2019-05-23) in USD | $15.3 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 35 Publicly-Listed Biotechs Companies | 19.23x |
| United States of America Market PE Ratio | Median Figure of 3,085 Publicly-Listed Companies | 17.79x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Puma Biotechnology.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:PBYI Share Price ÷ EPS (both in USD) = 15.3 ÷ -2.60 |
-5.88x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Puma Biotechnology is loss making, we can't compare its value to the US Biotechs industry average.
- Puma Biotechnology is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Puma Biotechnology's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -5.88x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts |
67.3%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 28 Publicly-Listed Biotechs Companies | 1.26x |
| United States of America Market PEG Ratio | Median Figure of 2,123 Publicly-Listed Companies | 1.54x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Puma Biotechnology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Puma Biotechnology's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $1.13 |
| NasdaqGS:PBYI Share Price * | NasdaqGS (2019-05-23) in USD | $15.3 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 414 Publicly-Listed Biotechs Companies | 3.35x |
| United States of America Market PB Ratio | Median Figure of 5,201 Publicly-Listed Companies | 1.84x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:PBYI Share Price ÷ Book Value per Share (both in USD) = 15.3 ÷ 1.13 |
13.58x |
* Primary Listing of Puma Biotechnology.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Puma Biotechnology is overvalued based on assets compared to the US Biotechs industry average.
Value checks
We assess Puma Biotechnology's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Puma Biotechnology has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
PBYI Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Puma Biotechnology's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Puma Biotechnology's earnings growth is expected to exceed the United States of America market average.
- Puma Biotechnology's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGS:PBYI Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts | 67.3% |
| NasdaqGS:PBYI Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts | 13.2% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 22.6% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 17.7% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.7% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 8 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 491 | 128 | 104 | 5 |
| 2022-12-31 | 433 | 99 | 51 | 5 |
| 2021-12-31 | 361 | 60 | -11 | 6 |
| 2020-12-31 | 303 | 17 | -79 | 8 |
| 2019-12-31 | 303 | 49 | -86 | 8 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 284 | -34 | -99 |
| 2018-12-31 | 251 | -24 | -114 |
| 2018-09-30 | 202 | -67 | -147 |
| 2018-06-30 | 145 | -114 | -210 |
| 2018-03-31 | 94 | -143 | -243 |
| 2017-12-31 | 28 | -172 | -292 |
| 2017-09-30 | 6 | -178 | -301 |
| 2017-06-30 | -158 | -289 | |
| 2017-03-31 | -143 | -278 | |
| 2016-12-31 | -142 | -276 | |
| 2016-09-30 | -134 | -265 | |
| 2016-06-30 | -136 | -260 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 8 Analyst Estimates (S&P Global) | See Below |
All data from Puma Biotechnology Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 2.26 | 4.63 | 0.69 | 4.00 |
| 2022-12-31 | 1.13 | 2.87 | -0.02 | 4.00 |
| 2021-12-31 | -0.39 | 0.17 | -1.20 | 6.00 |
| 2020-12-31 | -1.87 | -1.00 | -3.02 | 9.00 |
| 2019-12-31 | -2.31 | -0.63 | -3.07 | 10.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | -2.60 |
| 2018-12-31 | -2.99 |
| 2018-09-30 | -3.89 |
| 2018-06-30 | -5.59 |
| 2018-03-31 | -6.52 |
| 2017-12-31 | -7.85 |
| 2017-09-30 | -8.19 |
| 2017-06-30 | -8.14 |
| 2017-03-31 | -8.08 |
| 2016-12-31 | -8.29 |
| 2016-09-30 | -8.16 |
| 2016-06-30 | -8.01 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Puma Biotechnology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Puma Biotechnology's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Puma Biotechnology has a total score of 4/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
PBYI Past Performance
How has Puma Biotechnology performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Puma Biotechnology does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Puma Biotechnology's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Puma Biotechnology's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Puma Biotechnology Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 283.54 | -99.32 | 155.09 | 153.66 |
| 2018-12-31 | 250.99 | -113.58 | 146.19 | 164.85 |
| 2018-09-30 | 201.52 | -146.96 | 136.11 | 176.78 |
| 2018-06-30 | 144.97 | -209.94 | 140.10 | 189.93 |
| 2018-03-31 | 94.20 | -243.44 | 124.89 | 199.93 |
| 2017-12-31 | 27.69 | -291.96 | 106.69 | 207.81 |
| 2017-09-30 | 6.08 | -300.54 | 92.29 | 213.95 |
| 2017-06-30 | -289.14 | 73.82 | 216.43 | |
| 2017-03-31 | -277.90 | 61.16 | 217.39 | |
| 2016-12-31 | -276.01 | 53.80 | 222.80 | |
| 2016-09-30 | -265.07 | 46.92 | 218.84 | |
| 2016-06-30 | -259.71 | 41.71 | 218.79 | |
| 2016-03-31 | -257.80 | 34.98 | 223.95 | |
| 2015-12-31 | -239.28 | 31.81 | 208.47 | |
| 2015-09-30 | -225.05 | 30.27 | 195.56 | |
| 2015-06-30 | -200.48 | 25.33 | 175.73 | |
| 2015-03-31 | -174.63 | 23.70 | 151.35 | |
| 2014-12-31 | -141.97 | 19.36 | 122.92 | |
| 2014-09-30 | -110.43 | 14.28 | 96.39 | |
| 2014-06-30 | -88.87 | 12.68 | 76.37 | |
| 2014-03-31 | -62.67 | 11.04 | 51.81 | |
| 2013-12-31 | -54.66 | 9.79 | 45.05 | |
| 2013-09-30 | -60.63 | 20.47 | 40.32 | |
| 2013-06-30 | -72.20 | 26.30 | 46.03 | |
| 2013-03-31 | -74.31 | 25.80 | 48.60 | |
| 2012-12-31 | -74.35 | 24.81 | 49.64 | |
| 2012-09-30 | -62.29 | 20.11 | 42.18 | |
| 2012-06-30 | -36.78 | 12.35 | 24.40 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Puma Biotechnology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Puma Biotechnology has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Puma Biotechnology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Puma Biotechnology's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Puma Biotechnology has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
PBYI Health
How is Puma Biotechnology's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Puma Biotechnology's finances.
The net worth of a company is the difference between its assets and liabilities.
- Puma Biotechnology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Puma Biotechnology's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Puma Biotechnology Company Filings, last reported 1 month ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 43.47 | 179.73 | 150.40 |
| 2018-12-31 | 34.31 | 151.89 | 165.42 |
| 2018-09-30 | 45.91 | 121.05 | 127.95 |
| 2018-06-30 | 38.30 | 120.27 | 134.51 |
| 2018-03-31 | 57.46 | 48.56 | 78.55 |
| 2017-12-31 | 53.30 | 48.48 | 81.70 |
| 2017-09-30 | 79.17 | 0.00 | 106.34 |
| 2017-06-30 | 120.11 | 0.00 | 151.65 |
| 2017-03-31 | 167.39 | 0.00 | 193.98 |
| 2016-12-31 | 209.82 | 0.00 | 229.48 |
| 2016-09-30 | 91.15 | 0.00 | 108.93 |
| 2016-06-30 | 127.08 | 0.00 | 143.79 |
| 2016-03-31 | 164.94 | 0.00 | 181.21 |
| 2015-12-31 | 206.01 | 0.00 | 215.89 |
| 2015-09-30 | 244.84 | 0.00 | 247.78 |
| 2015-06-30 | 274.78 | 0.00 | 282.37 |
| 2015-03-31 | 304.34 | 0.00 | 310.33 |
| 2014-12-31 | 117.05 | 0.00 | 141.33 |
| 2014-09-30 | 141.60 | 0.00 | 153.86 |
| 2014-06-30 | 167.04 | 0.00 | 178.35 |
| 2014-03-31 | 198.79 | 0.00 | 196.11 |
| 2013-12-31 | 83.99 | 0.00 | 83.95 |
| 2013-09-30 | 94.76 | 0.00 | 95.64 |
| 2013-06-30 | 107.03 | 0.00 | 107.52 |
| 2013-03-31 | 118.28 | 0.00 | 118.72 |
| 2012-12-31 | 128.91 | 0.00 | 137.41 |
| 2012-09-30 | 9.00 | 0.00 | 33.35 |
| 2012-06-30 | 28.04 | 0.00 | 41.00 |
- Puma Biotechnology's level of debt (413.4%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (0% vs 413.4% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Puma Biotechnology has sufficient cash runway for more than 3 years based on current free cash flow.
- Puma Biotechnology has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -17.6% each year.
Financial health checks
We assess Puma Biotechnology's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Puma Biotechnology has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
PBYI Dividends
What is Puma Biotechnology's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Puma Biotechnology
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Puma Biotechnology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Puma Biotechnology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 8 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 19 Stocks | 2.4% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2005 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | 0.00 | 2.00 |
| 2020-12-31 | 0.00 | 3.00 |
| 2019-12-31 | 0.00 | 3.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Puma Biotechnology has not reported any payouts.
- Unable to verify if Puma Biotechnology's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Puma Biotechnology's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Puma Biotechnology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Puma Biotechnology has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
PBYI Management
CEO
| COMPENSATION | $6,152,550 |
| AGE | 48 |
| TENURE AS CEO | 7.6 years |
CEO Bio
Mr. Alan H. Auerbach is the Founder of Puma Biotechnology, Inc. and has been its Executive Chairman, Chief Executive Officer and President since October 4, 2011 and serves as its Secretary. Mr. Auerbach is a Private Equity Partner at Burrill Private Equity. He serves as an Advisor at Los Angeles Syndicate of Technology, Inc. He founded Cougar Biotechnology, Inc. in May 2003 and served as its Chief Executive Officer and President since May 2003. From July 2009 to January 2010, he served as the Co-Chairman of the integration steering committee that provides leadership and oversight for the development and global commercialization of Cougar’s lead product candidate, abiraterone acetate. Prior to Cougar, from June 1998 to April 2003 Mr. Auerbach served as a Vice President and Senior Research Analyst at Wells Fargo Securities, LLC, Research Division, where he was responsible for research coverage of small and middle capitalization biotechnology companies, with a focus on companies in the field of oncology. He had primary responsibility for technical, scientific and clinical due diligence, as well as selection of biotechnology companies followed by Wells Fargo. During 2002, he ranked second in the NASDAQ/Starmine survey of analyst performance for stock picking in biotechnology. From August 1997 to May 1998, Mr. Auerbach was a Vice President, Research Analyst at the Seidler Companies, Inc., Research Division where he was responsible for research coverage of small capitalization biotechnology companies. Prior to his work as a biotechnology analyst, he worked for Diagnostic Products Corporation, where he designed and implemented clinical trials in the field of oncology. He has been an Executive Director of Puma Biotechnology, Inc., since 2011. He served as an Independent Director of Radius Health, Inc., from May 24, 2011 to December 29, 2017. He served as a Member of Cougar Biotechnology, Inc. from May 2003 to July 2009. Mr. Auerbach received an M.S. In Biomedical Enginerring from the University of Southern California and a B.S. in Biomedical Engineering from Boston University.
CEO Compensation
- Alan's compensation has increased whilst company is loss making.
- Alan's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Puma Biotechnology management team in years:
- The tenure for the Puma Biotechnology management team is about average.
Management Team
Alan Auerbach
Founder
$6M
48
7.6 yrs
Maximo Nougues
CFO & Principal Accounting Officer
$2M
49
0.5 yrs
Richard Bryce
Chief Medical & Scientific Officer
$2M
61
1.8 yrs
Steven Lo
Chief Commercial Officer
$2M
51
3.7 yrs
Douglas Hunt
Senior Vice President of Regulatory Affairs
$7M
53
1.3 yrs
Mariann Ohanesian
Senior Director of Investor Relations
7.5 yrs
Charon Spencer
Vice President of Human Resources
Board of Directors Tenure
Average tenure and age of the Puma Biotechnology board of directors in years:
- The tenure for the Puma Biotechnology board of directors is about average.
Board of Directors
Alan Auerbach
Founder
$6M
48
7.6 yrs
Jay Moyes
Lead Independent Director
$386K
64
Troy Wilson
Independent Director
$356K
49
5.6 yrs
Frank Zavrl
Independent Director
$358K
52
3.7 yrs
Adrian Senderowicz
Independent Director
$353K
54
3.8 yrs
Mike Miller
Director
$1M
61
1.3 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 06. May 19 | Sell | Alan Auerbach | Individual | 02. May 19 | 02. May 19 | -477 | $32.38 | $-15,445 | ||
| 06. May 19 | Sell | Richard Bryce | Individual | 02. May 19 | 02. May 19 | -85 | $32.38 | $-2,752 | ||
| 03. Apr 19 | Sell | Richard Bryce | Individual | 02. Apr 19 | 02. Apr 19 | -88 | $35.78 | $-3,149 | ||
| 03. Apr 19 | Sell | Alan Auerbach | Individual | 02. Apr 19 | 02. Apr 19 | -491 | $35.79 | $-17,573 | ||
| 22. Mar 19 | Sell | Alan Auerbach | Individual | 04. Mar 19 | 04. Mar 19 | -496 | $38.62 | $-19,156 | ||
| 22. Mar 19 | Sell | Richard Bryce | Individual | 04. Mar 19 | 04. Mar 19 | -88 | $38.66 | $-3,402 | ||
| 06. Feb 19 | Sell | Richard Bryce | Individual | 04. Feb 19 | 04. Feb 19 | -89 | $27.77 | $-2,472 | ||
| 06. Feb 19 | Sell | Charles Eyler | Individual | 04. Feb 19 | 04. Feb 19 | -87 | $27.64 | $-2,405 | ||
| 06. Feb 19 | Sell | Alan Auerbach | Individual | 04. Feb 19 | 04. Feb 19 | -345 | $27.80 | $-9,591 | ||
| 04. Jan 19 | Sell | Richard Bryce | Individual | 03. Jan 19 | 03. Jan 19 | -1,210 | $20.67 | $-25,011 | ||
| 04. Jan 19 | Sell | Alan Auerbach | Individual | 03. Jan 19 | 03. Jan 19 | -4,424 | $20.67 | $-91,444 | ||
| 04. Jan 19 | Sell | Charles Eyler | Individual | 03. Jan 19 | 03. Jan 19 | -1,210 | $20.67 | $-25,011 | ||
Management checks
We assess Puma Biotechnology's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Puma Biotechnology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
PBYI News
Simply Wall St News
Have Insiders Been Selling Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares?
So we'll take a look at whether insiders have been buying or selling shares in Puma Biotechnology, Inc. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' Check out our latest analysis for Puma Biotechnology The Last 12 Months Of Insider Transactions At Puma Biotechnology Over the last year, we can see that the biggest insider sale was by the Founder, Alan Auerbach, for US$91k worth of shares, at about US$20.67 per share. … Insiders sold Puma Biotechnology shares recently, but they didn't buy any.
Simply Wall St - – Full articleDoes Puma Biotechnology, Inc.'s (NASDAQ:PBYI) CEO Pay Compare Well With Peers?
This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Alan Auerbach's Compensation Compare With Similar Sized Companies. … has a market cap of US$1.3b, and is paying total annual CEO compensation of US$2.8m.
Simply Wall St - – Full articleIntroducing Puma Biotechnology, The Stock That Tanked 78%
Puma Biotechnology isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … When a company doesn't yet make profits, we'd generally expect to see good revenue growth. … Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.
Simply Wall St - – Full articleWhen Will Puma Biotechnology Inc (NASDAQ:PBYI) Turn A Profit?
Puma Biotechnology Inc's (NASDAQ:PBYI):. … Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. … The US$841m market-cap posted a loss in its most recent financial year of -US$292.0m and a latest trailing-twelve-month loss of -US$147.0m shrinking the gap between loss and breakeven.
Simply Wall St - – Full articleDoes Puma Biotechnology Inc's (NASDAQ:PBYI) CEO Pay Compare Well With Peers?
Understanding how CEOs are incentivised to run and grow their company is an important aspect of investing in a stock. … Incentives can be in the form of compensation, which should always be structured in a way that promotes value-creation to shareholders. … CEOs leading companies of similar size and profitability
Simply Wall St - – Full articleWant To Invest In Puma Biotechnology Inc (NASDAQ:PBYI)? Here's How It Performed Lately
Today I will examine Puma Biotechnology Inc's (NASDAQ:PBYI) latest earnings update (31 March 2018) and compare these figures against its performance over the past couple of years, in addition to how the rest of PBYI's industry performed. … Were PBYI's earnings stronger than its past performances and the industry. … PBYI is loss-making, with the most recent trailing twelve-month earnings of -US$243.43m (from 31 March 2018), which compared to last year has become.
Simply Wall St - – Full articleInterested In Healthcare? Why Puma Biotechnology Inc (NASDAQ:PBYI) May Be The Entry Point
Check out our latest analysis for Puma Biotechnology What’s the catalyst for Puma Biotechnology's sector growth? … Puma Biotechnology lags the pack with its lower growth rate of 19.33% over the past year, which indicates the company will be growing at a slower pace than its biotech peers. … If Puma Biotechnology has been on your watchlist for a while, now may be the time to enter into the stock, if you like its growth prospects and are not highly concentrated in the biotech industry.
Simply Wall St - – Full articleOne Thing To Consider Before Buying Puma Biotechnology Inc (NASDAQ:PBYI)
Generally, an investor should consider two types of risk that impact the market value of PBYI. … PBYI, with its market capitalisation of US$1.93B, is a small-cap stock, which generally have higher beta than similar companies of larger size. … I test PBYI’s ratio of fixed assets to total assets in order to determine how high the risk is associated with this type of constraint.
Simply Wall St - – Full articleHow Much Did Puma Biotechnology Inc's (NASDAQ:PBYI) CEO Pocket Last Year?
In this exercise, I will use profits as a proxy for Auerbach's performance. … Typically I would look at market cap and earnings as a proxy for performance, however, PBYI's negative earnings lower the usefulness of my formula. … If you have not done so already, I urge you to complete your research by taking a look at the following: Governance: To find out more about PBYI's governance, look through our infographic report of the company's board and management.
Simply Wall St - – Full articleShould You Be Concerned About Puma Biotechnology Inc's (NASDAQ:PBYI) Shareholders?
13.30% ownership of PBYI insiders is large enough to make an impact on shareholder returns. … It may be interesting to take a look at what company insiders have been doing with their holdings lately. … This is an encouraging sign for investors as these investors tend to be active strategist in companies, focusing on increasing operational and capital efficiency for the firm.Next Steps: With significant institutional ownership, including active hedge, existing investors should seek a margin of safety when investing in PBYI.
Simply Wall St - – Full articlePBYI Company Info
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Details
| Name: | Puma Biotechnology, Inc. |
| PBYI | |
| Exchange: | NasdaqGS |
| Founded: | 2010 |
| $590,770,439 | |
| 38,612,447 | |
| Website: | http://www.pumabiotechnology.com |
| Address: |
Puma Biotechnology, Inc. 10880 Wilshire Boulevard, Suite 2150, Los Angeles, California, 90024, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | PBYI | Common Stock | Nasdaq Global Select | US | USD | 18. Apr 2012 | |
| DB | 0PB | Common Stock | Deutsche Boerse AG | DE | EUR | 18. Apr 2012 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/24 00:25 |
| End of day share price update: | 2019/05/23 00:00 |
| Last estimates confirmation: | 2019/05/11 |
| Last earnings filing: | 2019/05/10 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
